- ►ahajournals.org SM Haffner, AS Greenberg, WM Weston, H Chen, K … - Circulation, 2002 - Am Heart Assoc Background— Markers of systemic inflammation (eg, C-reactive protein [CRP] and
interleukin-6 [IL-6]) have been proposed to be "nontraditional" risk factors for cardiovascular
disease in patients with type 2 diabetes mellitus. Matrix metalloproteinase-9 (MMP-9) has ... Cited by 837 - Related articles - BL Direct - All 9 versions
- ►ahajournals.org FA Masoudi, SE Inzucchi, Y Wang, EP Havranek, JAM … - Circulation, 2005 - Am Heart Assoc Methods and Results— We conducted a retrospective cohort study of 16 417 Medicare beneficiaries
with diabetes discharged after hospitalization with the principal discharge diagnosis of heart
failure. The association between antidiabetic drug prescriptions and outcomes was ... Cited by 195 - Related articles - All 10 versions
C Duval, G Chinetti, F Trottein, JC Fruchart, B … - Trends in Molecular …, 2002 - Elsevier Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors that
regulate lipid and lipoprotein metabolism, glucose homeostasis and inflammation. The PPAR
family consists of three proteins, α, β/δ and γ. Recent data suggest that PPARα and γ ... Cited by 143 - Related articles - All 6 versions
- ►ahajournals.org D Fukumura, A Ushiyama, DG Duda, L Xu, J Tam, … - Circulation …, 2003 - Am Heart Assoc With an increasing incidence of obesity worldwide, rational strategies are needed to control
adipogenesis. Growth of any tissue requires the formation of a functional and mature
vasculature. To gain mechanistic insight into the link between active adipogenesis and ... Cited by 134 - Related articles - All 5 versions
- ►ahajournals.org CH Wang, N Ciliberti, SH Li, PE Szmitko, RD Weisel, … - Circulation, 2004 - Am Heart Assoc Methods and Results— C57/BL6 mice, treated with or without rosiglitazone (8 mg/kg per
day), a PPAR- agonist, underwent femoral angioplasty. Rosiglitazone treatment attenuated neointimal
formation (intima/media ratio: 0.98±0.12 [rosiglitazone] versus 3.1±0.5 [control]; P<0.001; ... Cited by 129 - Related articles - BL Direct - All 9 versions
V Fonseca - The American journal of medicine, 2003 - Elsevier Treatment of diabetes mellitus with medications, including insulin, sulfonylureas, and thiazolidinediones
(TZDs), often leads to weight gain through a variety of mechanisms. Weight gain can have adverse
consequences for patients with type 2 diabetes, many of whom are overweight or obese, ... Cited by 107 - Related articles - All 8 versions
- ►jbc.org DH Cho, YJ Choi, SA Jo, I Jo - Journal of Biological Chemistry, 2004 - ASBMB Recently, peroxisome proliferator-activated receptor (PPAR ) ligands have been reported to increase
endothelial NO, but the signaling mechanisms involved are unknown. Using troglitazone, a PPAR
ligand known as an antidiabetic compound, we investigated the molecular mechanism of ... Cited by 104 - Related articles - BL Direct - All 6 versions
- ►mayoclinicproceedings.com [PDF] A Kermani, A Garg - Mayo Clinic Proceedings, 2003 - mayoclinproc.highwire.org • Objective: To evaluate the effect of thiazolidinediones on the development of cardiac failure
and pulmonary edema during treatment of type 2 diabetes mellitus. • Patients and Methods: We
retrospectively reviewed the medical records of 6 men (aged 66 to 78 years) treated at ... Cited by 102 - Related articles - BL Direct - All 12 versions
S Mudaliar, MD, FACE, AR Chang, MD, RR Henry, MD - Endocrine Practice, 2003 - AACE The thiazolidinediones are peroxisome proliferator- activated receptor-γ agonists that constitute
a new class of orally administered antidiabetic compounds that decrease insulin resistance in
patients with type 2 diabetes (1-4). Resistance to insulin-mediated glucose uptake is a ... Cited by 102 - Related articles - BL Direct - All 2 versions
